|
#3
23.09.2009, 19:20
|
||||
|
||||
|
ACCF/AHA 2009 Performance Measures for Primary
Prevention of Cardiovascular Disease in Adults [Ссылки доступны только зарегистрированным пользователям ] A Curriculum on Prevention of Cardiovascular Disease [Ссылки доступны только зарегистрированным пользователям ] 
|
|
#4
24.09.2009, 10:34
|
||||
|
||||
|
SPIRIT IV: EES looks superior to PES at 1 year
[Ссылки доступны только зарегистрированным пользователям ] COMPARE: EES reduces cardiovascular events vs PES [Ссылки доступны только зарегистрированным пользователям ] ISAR-DESIRE 2: No difference in type of DES for treating in-stent restenosis [Ссылки доступны только зарегистрированным пользователям ] SIRTAX-LATE: 5-year results show equal outcomes with PES and SES [Ссылки доступны только зарегистрированным пользователям ] ENDEAVOR IV: ZES stents beat out PES at 3 years [Ссылки доступны только зарегистрированным пользователям ]
|
|
#5
25.09.2009, 18:40
|
||||
|
||||
|
COGENT: No CV harm, but large GI benefit with PPI and clopidogrel
[Ссылки доступны только зарегистрированным пользователям ] CURRENT OASIS 7 SUBSTUDY: High-dose clopidogrel beneficial in STEMI PCI [Ссылки доступны только зарегистрированным пользователям ] CHARISMA GENOMICS SUBSTUDY: Only 2C19 homozygotes show muted clopidogrel effect [Ссылки доступны только зарегистрированным пользователям ] TRITON-TIMI 38 ECONOMIC SUBSTUDY: Prasugrel very cost-effective in PCI for ACS; reduced CV hospitalization seen [Ссылки доступны только зарегистрированным пользователям ] PLATO INVASIVE: Benefit of ticagrelor over clopidogrel in invasive stategy [Ссылки доступны только зарегистрированным пользователям ]
|
|
#6
26.09.2009, 10:50
|
||||
|
||||
|
SYMPLICITY I: Novel percutaneous technique for hypertension shows promise
[Ссылки доступны только зарегистрированным пользователям ] HORIZONS-AMI: Bivalirudin remains non-inferior in STEMI [Ссылки доступны только зарегистрированным пользователям ] HORIZONS-AMI Stent: PES beats BMS in STEMI at 2 years [Ссылки доступны только зарегистрированным пользователям ] BCIS-1: No benefit of routine IABP insertion for high-risk PCI [Ссылки доступны только зарегистрированным пользователям ] NORDIC-BALTIC BIFURCATION STUDY III: No benefit with kissing balloons [Ссылки доступны только зарегистрированным пользователям ] FAUST: Ultrasound guidance for femoral access may help [Ссылки доступны только зарегистрированным пользователям ]
|
|
#7
29.09.2009, 18:31
|
||||
|
||||
|
Обзор по обмену железа наглядно плюс его коррекция при лечении ХСН и ХПН в свободном доступе:
Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009;14 Suppl 1:22-33. [Ссылки доступны только зарегистрированным пользователям ]
|
|
|
|
#8
01.10.2009, 06:46
|
||||
|
||||
|
Избирательные ингибиторы захвата серотонина у беременных могут вызывать ВПС плода
Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study; Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH; British Medical Journal (BMJ) 339 b3569 (2009)
OBJECTIVE: To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations. DESIGN: Population based cohort study. PARTICIPANTS: 493 113 children born in Denmark, 1996-2003. MAIN OUTCOME MEASURE: Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005. RESULTS: Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low-for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI. CONCLUSION: There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI.
|
|
#9
01.10.2009, 06:48
|
||||
|
||||
|
Еще раз про пантопразол у пациентов, получающих клопидогрель
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study; Frere C, Cuisset T, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL; Journal of the American College of Cardiology (JACC) 54 (13), 1149-53 (Sep 2009)
OBJECTIVES: This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on platelet response to clopidogrel after coronary stenting for non-ST-segment elevation acute coronary syndrome (NSTE ACS). BACKGROUND: Use of omeprazole has been reported to significantly decrease the clopidogrel antiplatelet effect because of cytochrome P450 interaction. Because all PPIs are metabolized by CYP2C19, but to a varying degree, we hypothesized that the reported negative omeprazole-clopidogrel drug interaction may not be caused by a class effect. METHODS: A total of 104 patients undergoing coronary stenting for NSTE ACS were prospectively included and randomized to omeprazole or pantoprazole 20 mg. They received at discharge 75-mg aspirin and 150-mg clopidogrel. Platelet reactivity index (PRI) vasoactive stimulated phosphoprotein (VASP) was used to assess clopidogrel response and adenosine diphosphate (ADP)-induced aggregation for platelet reactivity (ADP-Ag). RESULTS: After 1 month, patients receiving pantoprazole had a significantly better platelet response to clopidogrel as assessed with the PRI VASP: 36 +/- 20% versus 48 +/- 17% (p = 0.007). We identified more clopidogrel nonresponders in the omeprazole group than in the pantoprazole group: 44% versus 23% (p = 0.04), odds ratio: 2.6 (95% confidence interval: 1.2 to 6.2). Conversely, we did not observe any significant difference in platelet reactivity with ADP-Ag between the omeprazole and pantoprazole groups: 52 +/- 15% and 50 +/- 18%, respectively (p = 0.29). CONCLUSIONS: The present findings suggest the preferential use of pantoprazole compared with omeprazole in patients receiving clopidogrel to avoid any potential negative interaction with CYP2C19.
|
|
#11
08.10.2009, 09:12
|
|||
|
|||
|
Дефибриллятр после ИМ не нужен (IRIS)
Defibrillator Implantation Early after Myocardial Infarction Gerhard Steinbeck at al. NEJM [Ссылки доступны только зарегистрированным пользователям ] Background The rate of death, including sudden cardiac death, is highest early after a myocardial infarction. Yet current guidelines do not recommend the use of an implantable cardioverter–defibrillator (ICD) within 40 days after a myocardial infarction for the prevention of sudden cardiac death. We tested the hypothesis that patients at increased risk who are treated early with an ICD will live longer than those who receive optimal medical therapy alone. Methods This randomized, prospective, open-label, investigator-initiated, multicenter trial registered 62,944 unselected patients with myocardial infarction. Of this total, 898 patients were enrolled 5 to 31 days after the event if they met certain clinical criteria: a reduced left ventricular ejection fraction ([Изображения доступны только зарегистрированным пользователям]40%) and a heart rate of 90 or more beats per minute on the first available electrocardiogram (ECG) (criterion 1: 602 patients), nonsustained ventricular tachycardia ([Изображения доступны только зарегистрированным пользователям]150 beats per minute) during Holter monitoring (criterion 2: 208 patients), or both criteria (88 patients). Of the 898 patients, 445 were randomly assigned to treatment with an ICD and 453 to medical therapy alone. Results During a mean follow-up of 37 months, 233 patients died: 116 patients in the ICD group and 117 patients in the control group. Overall mortality was not reduced in the ICD group (hazard ratio, 1.04; 95% confidence interval [CI], 0.81 to 1.35; P=0.78). There were fewer sudden cardiac deaths in the ICD group than in the control group (27 vs. 60; hazard ratio, 0.55; 95% CI, 0.31 to 1.00; P=0.049), but the number of nonsudden cardiac deaths was higher (68 vs. 39; hazard ratio, 1.92; 95% CI, 1.29 to 2.84; P=0.001). Hazard ratios were similar among the three groups of patients categorized according to the enrollment criteria they met (criterion 1, criterion 2, or both). Conclusions Prophylactic ICD therapy did not reduce overall mortality among patients with acute myocardial infarction and clinical features that placed them at increased risk. (ClinicalTrials.gov number, NCT00157768 [Ссылки доступны только зарегистрированным пользователям ] .)
|
|
#12
03.10.2009, 13:09
|
||||
|
||||
|
10 points to remember about the ACCF/AHA 2009 performance measures for primary prevention of CVD (J Am Coll Cardiol).
[Ссылки доступны только зарегистрированным пользователям ] Treatment with a selective endothelin-receptor antagonist to reduce BP. [Ссылки доступны только зарегистрированным пользователям ] Just Launched: Use Cardiosource's new On-Label Resource Centers to get current information on appropriate use of certain therapeutics, including Multaq. [Ссылки доступны только зарегистрированным пользователям ] TCT 2009: Get complete coverage of TCT, including videos and presentation slides. [Ссылки доступны только зарегистрированным пользователям ] New for your patients: What you need to know about blood thinners. [Ссылки доступны только зарегистрированным пользователям ] New Expert Opinion: Drs. Bernhard Bischoff and Joerg Hausleiter on Radiation Dose in Cardiac CT. [Ссылки доступны только зарегистрированным пользователям ] Prospective Validation of the Prognostic Usefulness of Brain Natriuretic Peptide in Asymptomatic Patients With Chronic Severe Mitral Regurgitation Pizarro R, Bazzino OO, Oberti PF, et al. J Am Coll Cardiol 2009;54:1099-1106. Study Question: What is the independent and additive prognostic value of brain natriuretic peptide (BNP) in patients with severe asymptomatic mitral regurgitation and normal left ventricular function? [Ссылки доступны только зарегистрированным пользователям ] Fluvastatin and Perioperative Events in Patients Undergoing Vascular Surgery Schouten O, Boersma E, Hoeks SE, et al. N Engl J Med 2009;361:980-989. Study Question: Does perioperative statin therapy improve postoperative incidence of adverse cardiac events in patients undergoing vascular surgery? [Ссылки доступны только зарегистрированным пользователям ] The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation Singer DE, Chang Y, Fang MC, et al. Ann Intern Med 2009;151:297-305. Study Question: What is the net clinical benefit (considering thromboembolic and hemorrhagic risk) of warfarin therapy in patients with atrial fibrillation (AF)? [Ссылки доступны только зарегистрированным пользователям ] Improved Oral Anticoagulation After a Dietary Vitamin K-Guided Strategy: A Randomized Controlled Trial de Assis MC, Rabelo ER, Ávila CW, Polanczyk CA, Rohde LE. Circulation 2009;120:1115-1122. Study Question: Will a strategy of modifying dietary vitamin K intake improve management of oral warfarin therapy compared with a conventional dosage adjustment strategy? [Ссылки доступны только зарегистрированным пользователям ] Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. JAMA 2009;302:1186-1194. Study Question: What is the effect of insulin alone or combined with metformin in lowering levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and soluble tumor necrosis factor receptor 2 (sTNFr2) in patients with recent-onset type 2 diabetes mellitus? [Ссылки доступны только зарегистрированным пользователям ] Effects of Donor Pretreatment With Dopamine on Graft Function After Kidney Transplantation: A Randomized Controlled Trial Schnuelle P, Gottmann U, Hoeger S, et al. JAMA 2009;302:1067-1075. Study Question: What is the effect of pretreatment of brain-dead donors with low-dose dopamine on early graft function in human renal transplant recipients? [Ссылки доступны только зарегистрированным пользователям ] Risk of Hyperkalemia in Nondiabetic Patients With Chronic Kidney Disease Receiving Antihypertensive Therapy Weinberg JM, Appel LJ, Bakris G, et al., on behalf of the African American Study of Hypertension and Kidney Disease Collaborative Research Group. Arch Intern Med 2009;169:1587-1594. Study Question: What is the incidence and what are the factors associated with hyperkalemia in patients with chronic kidney disease (CKD) treated with angiotensin-converting enzyme inhibitors (ACEIs) and other antihypertensive drugs? [Ссылки доступны только зарегистрированным пользователям ]
|
|
#13
09.10.2009, 20:39
|
||||
|
||||
|
GDF-15 Predicts M&M After CRT
[Ссылки доступны только зарегистрированным пользователям ] Statin therapy and risk of developing type 2 DM (Diabetes Care). [Ссылки доступны только зарегистрированным пользователям ] Prognostic value of stress myocardial perfusion and late gadolinium enhancement imaging by CMR (Circulation). [Ссылки доступны только зарегистрированным пользователям ] Immediate Risk-Stratification Improves Survival (IRIS). [Ссылки доступны только зарегистрированным пользователям ]
|
|
#15
10.10.2009, 08:50
|
|||
|
|||
|
Цитата:
Вопрос примерно из серии: "А Вы весь журнал Circulation, прочитываете от корки до корки?". Каждый читает, что ему интересно.
|
Комбинированный вид
